Table 3.

Impact of clinical and correlative variables on overall survival

Evaluable patients (N = 23)
VariableNo. of patientsaHR95% CIP
Age
 >65 y92.720.98–7.580.05
 ≤65 y14
Gender
 Male140.630.25–1.600.33
 Female9
Baseline CA 19-9
 >1,000 U/mL152.150.82–5.630.12
 ≤1,000 U/mL8
Baseline SHH
 >200120.760.29–1.990.76
 ≤2008
Baseline Ki-67
 >30%130.680.26–1.790.43
 ≤30%7
Baseline GLI1
 >0.591.010.42–2.460.98
 ≤0.514
Baseline PTCH1
 >2.0110.790.33–1.890.60
 ≤2.012
Baseline fibrosis
 >50%140.440.18–1.100.08
 ≤50%9
Baseline CSCs
 >5%90.750.30–1.860.54
 ≤5%13
Change in Ki-67, after 3 wks
 Decrease90.870.32–2.350.79
 Increase8
Change in GLI1, after 3 wks
 >75% decrease150.850.32–2.260.74
 ≤75% decrease, or increase6
Change in PTCH1, after 3 wks
 Decrease190.790.26–2.390.68
 Increase4
Change in fibrosis, after 3 wks
 Decrease101.070.44–2.610.89
 Increase12
Change in CSCs, after 3 wks
 Decrease110.620.24–1.600.32
 Increase10
CA 19-9 response, best overall
 >50% decrease60.130.03–0.600.01
 ≤50% decrease, or increase13
  • aNumber of patients may be less if both pretreatment and posttreatment samples were not available.